Deal Watch: Sanofi, Boehringer Swap Side Businesses

21 Dec 2015
News

Executive Summary

Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical
Subjects
Deals

Related Companies

Related Deals

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Deals

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS057339

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS057339

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Deal Watch: Sanofi, Boehringer Swap Side Businesses

News

Executive Summary

Related Content

Sanofi Looks To Lead In Consumer Following Trade With Boehringer Ingelheim

Bristol Advancing Two New Mechanisms In HIV, With Focus On Treatment-Experienced Patients

Topics

Related Companies

Related Deals

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert